Biodexa Pharmaceuticals PLC announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are scheduled for presentation at the prestigious 2024 Digestive Disease.
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Shares of Biodexa Pharmaceuticals Plc (BDRX) surged over 62% on Tuesday morning on positive data of eRapa in Familial Adenomatous Polyposis. BDRX is currently trading at $2.
Posting of Annual Report & Notice of AGM - Total Voting Rights tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Posting of Annual Report & Notice of AGM globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.